Literature DB >> 36029004

Combined docking and machine learning identify key molecular determinants of ligand pharmacological activity on β2 adrenoceptor.

Mireia Jiménez-Rosés1,2, Bradley Angus Morgan1,3,4,5, Maria Jimenez Sigstad1,2, Thuy Duong Zoe Tran1,6, Rohini Srivastava1,6, Asuman Bunsuz1,2, Leire Borrega-Román1,2,7,8, Pattarin Hompluem1,2, Sean A Cullum1,2,5, Clare R Harwood1,2,5, Eline J Koers1,2, David A Sykes1,2, Iain B Styles1,3,4, Dmitry B Veprintsev1,2.   

Abstract

G protein-coupled receptors (GPCRs) are valuable therapeutic targets for many diseases. A central question of GPCR drug discovery is to understand what determines the agonism or antagonism of ligands that bind them. Ligands exert their action via the interactions in the ligand binding pocket. We hypothesized that there is a common set of receptor interactions made by ligands of diverse structures that mediate their action and that among a large dataset of different ligands, the functionally important interactions will be over-represented. We computationally docked ~2700 known β2AR ligands to multiple β2AR structures, generating ca 75 000 docking poses and predicted all atomic interactions between the receptor and the ligand. We used machine learning (ML) techniques to identify specific interactions that correlate with the agonist or antagonist activity of these ligands. We demonstrate with the application of ML methods that it is possible to identify the key interactions associated with agonism or antagonism of ligands. The most representative interactions for agonist ligands involve K972.68×67 , F194ECL2 , S2035.42×43 , S2045.43×44 , S2075.46×641 , H2966.58×58 , and K3057.32×31 . Meanwhile, the antagonist ligands made interactions with W2866.48×48 and Y3167.43×42 , both residues considered to be important in GPCR activation. The interpretation of ML analysis in human understandable form allowed us to construct an exquisitely detailed structure-activity relationship that identifies small changes to the ligands that invert their pharmacological activity and thus helps to guide the drug discovery process. This approach can be readily applied to any drug target.
© 2022 The Authors. Pharmacology Research & Perspectives published by British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics and John Wiley & Sons Ltd.

Entities:  

Keywords:  GPCRs; adrenoceptor; docking; drug discovery; machine learning; structure-activity relationship

Mesh:

Substances:

Year:  2022        PMID: 36029004      PMCID: PMC9418666          DOI: 10.1002/prp2.994

Source DB:  PubMed          Journal:  Pharmacol Res Perspect        ISSN: 2052-1707


  42 in total

1.  Structural interaction fingerprint (SIFt): a novel method for analyzing three-dimensional protein-ligand binding interactions.

Authors:  Zhan Deng; Claudio Chuaqui; Juswinder Singh
Journal:  J Med Chem       Date:  2004-01-15       Impact factor: 7.446

Review 2.  Structure and dynamics of GPCR signaling complexes.

Authors:  Daniel Hilger; Matthieu Masureel; Brian K Kobilka
Journal:  Nat Struct Mol Biol       Date:  2018-01-08       Impact factor: 15.369

3.  InChI - the worldwide chemical structure identifier standard.

Authors:  Stephen Heller; Alan McNaught; Stephen Stein; Dmitrii Tchekhovskoi; Igor Pletnev
Journal:  J Cheminform       Date:  2013-01-24       Impact factor: 5.514

Review 4.  Trends in GPCR drug discovery: new agents, targets and indications.

Authors:  Alexander S Hauser; Misty M Attwood; Mathias Rask-Andersen; Helgi B Schiöth; David E Gloriam
Journal:  Nat Rev Drug Discov       Date:  2017-10-27       Impact factor: 84.694

5.  Open Babel: An open chemical toolbox.

Authors:  Noel M O'Boyle; Michael Banck; Craig A James; Chris Morley; Tim Vandermeersch; Geoffrey R Hutchison
Journal:  J Cheminform       Date:  2011-10-07       Impact factor: 5.514

6.  Adrenaline-activated structure of β2-adrenoceptor stabilized by an engineered nanobody.

Authors:  Aaron M Ring; Aashish Manglik; Andrew C Kruse; Michael D Enos; William I Weis; K Christopher Garcia; Brian K Kobilka
Journal:  Nature       Date:  2013-09-22       Impact factor: 49.962

7.  ChEMBL: towards direct deposition of bioassay data.

Authors:  David Mendez; Anna Gaulton; A Patrícia Bento; Jon Chambers; Marleen De Veij; Eloy Félix; María Paula Magariños; Juan F Mosquera; Prudence Mutowo; Michal Nowotka; María Gordillo-Marañón; Fiona Hunter; Laura Junco; Grace Mugumbate; Milagros Rodriguez-Lopez; Francis Atkinson; Nicolas Bosc; Chris J Radoux; Aldo Segura-Cabrera; Anne Hersey; Andrew R Leach
Journal:  Nucleic Acids Res       Date:  2019-01-08       Impact factor: 16.971

8.  Function-specific virtual screening for GPCR ligands using a combined scoring method.

Authors:  Albert J Kooistra; Henry F Vischer; Daniel McNaught-Flores; Rob Leurs; Iwan J P de Esch; Chris de Graaf
Journal:  Sci Rep       Date:  2016-06-24       Impact factor: 4.379

Review 9.  Pharmacological treatment and current controversies in COPD.

Authors:  Mario Cazzola; Paola Rogliani; Daiana Stolz; Maria Gabriella Matera
Journal:  F1000Res       Date:  2019-08-29
View more
  1 in total

1.  Combined docking and machine learning identify key molecular determinants of ligand pharmacological activity on β2 adrenoceptor.

Authors:  Mireia Jiménez-Rosés; Bradley Angus Morgan; Maria Jimenez Sigstad; Thuy Duong Zoe Tran; Rohini Srivastava; Asuman Bunsuz; Leire Borrega-Román; Pattarin Hompluem; Sean A Cullum; Clare R Harwood; Eline J Koers; David A Sykes; Iain B Styles; Dmitry B Veprintsev
Journal:  Pharmacol Res Perspect       Date:  2022-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.